J. B. Chemicals & Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

J. B. Chemicals & Pharmaceuticals hat ein Gesamteigenkapital von ₹29.2B und eine Gesamtverschuldung von ₹3.8B, wodurch sich der Verschuldungsgrad auf 12.9% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen ₹39.9B bzw. ₹10.7B. J. B. Chemicals & Pharmaceuticals Das EBIT des Unternehmens beträgt ₹7.9B, so dass der Zinsdeckungsgrad 24.2 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von ₹4.6B.

Wichtige Informationen

12.9%

Verhältnis von Schulden zu Eigenkapital

₹3.78b

Verschuldung

Zinsdeckungsgrad	24.2x
Bargeld	₹4.60b
Eigenkapital	₹29.23b
Gesamtverbindlichkeiten	₹10.71b
Gesamtvermögen	₹39.94b

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 506943Die kurzfristigen Aktiva des Unternehmens (₹18.5B) übersteigen seine kurzfristigen Passiva (₹8.7B).

Langfristige Verbindlichkeiten: 506943Die kurzfristigen Vermögenswerte des Unternehmens (₹18.5B) übersteigen seine langfristigen Verbindlichkeiten (₹2.0B).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 506943 über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: 506943Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 1.7% auf 12.9% gestiegen.

Schuldendeckung: 506943Die Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (208.9%).

Zinsdeckung: 506943Die Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (24.2x Coverage) gut gedeckt.

J. B. Chemicals & Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

J. B. Chemicals & Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 06, 2024

Vice President of HR & Administration recently sold ₹5.8m worth of stock

Insider recently sold ₹2.1m worth of stock

Alkem Reportedly Joins $3 Billion Race for JB Chem as Torrent Pauses Talks

Insider recently sold ₹7.2m worth of stock

Key Executive recently sold ₹1.4m worth of stock

J. B. Chemicals & Pharmaceuticals Limited Approves Final Dividend for the Year Ended March 31, 2024

Torrent Pharma Reportedly is Said to Seek Raising $3 Billion for KKR's Stake in JB Chemicals

Torrent Pharmaceuticals Reportedly in Talks to Acquire KKR’s Stake in JB Chemicals

Full year 2024 earnings: EPS misses analyst expectations

Final dividend of ₹6.75 announced

J. B. Chemicals & Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 08, 2024

Insider recently sold ₹876k worth of stock

J. B. Chemicals & Pharmaceuticals Limited, Annual General Meeting, Aug 21, 2024

Insider recently sold ₹1.1m worth of stock

Full year 2024 earnings: EPS misses analyst expectations

J. B. Chemicals & Pharmaceuticals Limited Recommends Final Dividend for the Year 2023-2024

J. B. Chemicals & Pharmaceuticals Limited to Report Q4, 2024 Results on May 17, 2024

President of Global Business recently sold ₹5.6m worth of stock

Insider recently sold ₹3.2m worth of stock

Insider recently sold ₹2.3m worth of stock

KKR Reportedly Considers Selling Controlling Stake in JB Pharma

President of India Business recently sold ₹6.8m worth of stock

Price target increased by 7.1% to ₹1,870

Upcoming dividend of ₹5.50 per share at 0.6% yield

Dividend of ₹5.50 announced

J. B. Chemicals & Pharmaceuticals Limited Declares Interim Dividend for Financial Year 2023-24

J. B. Chemicals & Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 06, 2024

Price target increased by 7.6% to ₹1,700

Price target increased by 8.4% to ₹1,677

Less than half of directors are independent

J. B. Chemicals & Pharmaceuticals Limited Appoints Akshay Tanna as an Additional Director

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

J. B. Chemicals & Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 07, 2023

Price target increased by 17% to ₹1,606

CEO & Whole-Time Director recently sold ₹35m worth of stock

Investor sentiment deteriorates as stock falls 48%

J. B. Chemicals & Pharmaceuticals Limited Announces Cessation of Lakshay Kataria, Chief Financial Officer and Key Managerial Personnel, Effective November 30, 2023

CEO & Whole-Time Director recently sold ₹40m worth of stock

J. B. Chemicals & Pharmaceuticals Limited Approves Final Dividend for the Year Ended March 31, 2023

J.B. Chemicals & Pharmaceuticals Limited Announces Abbreviated New Drug Application Approval by US FDA

CEO & Whole-Time Director recently sold ₹40m worth of stock

Price target increased by 8.1% to ₹2,556

Upcoming dividend of ₹9.25 per share at 0.7% yield

J. B. Chemicals & Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 09, 2023

Full year 2023 earnings: EPS misses analyst expectations

CEO & Whole-Time Director recently sold ₹32m worth of stock

J. B. Chemicals & Pharmaceuticals Limited Recommends Final Dividend for the Year 2022-2023

Full year 2023 earnings: EPS misses analyst expectations

Insider recently sold ₹1.2m worth of stock

Insider recently sold ₹2.2m worth of stock

Insider recently sold ₹2.7m worth of stock

CEO & Whole-Time Director recently sold ₹20m worth of stock

CEO & Whole-Time Director recently sold ₹9.8m worth of stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

J. B. Chemicals & Pharmaceuticals Limited Declares Interim Dividend

J. B. Chemicals & Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 08, 2023

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) completed the acquisition of Razel Franchise For India And Nepal Region from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK).

CEO & Whole-Time Director recently sold ₹10m worth of stock

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) agreed to acquire Razel Franchise For India And Nepal Region from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) for INR3.1 billion.

JB Chemicals & Pharmaceuticals Limited (JB Pharma) Receives ANDA Approval For Venlafaxine Hydrochloride Extended-Release Tablets From USFDA

Price target increased to ₹2,292

High number of new and inexperienced directors

Second quarter 2023 earnings released: EPS: ₹14.37 (vs ₹12.65 in 2Q 2022)

J. B. Chemicals & Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 11, 2022

President of Global Business recently sold ₹7.0m worth of stock

CEO & Whole-Time Director recently sold ₹32m worth of stock

Torrent Pharma Reportedly Set to Acquire Curatio

Insider recently sold ₹1.3m worth of stock

Upcoming dividend of ₹8.00 per share

Full year 2022 earnings: EPS misses analyst expectations

J. B. Chemicals & Pharmaceuticals Limited Proposes Final Dividend for the Financial Year 2021-22, Payable on or After September 1, 2022

J. B. Chemicals & Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 04, 2022

J. B. Chemicals & Pharmaceuticals Limited, Annual General Meeting, Aug 24, 2022

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) agreed to acquire Portfolio of four paediatric brands from Dr. Reddy's Laboratories Limited (BSE:500124) for INR 98 million.